Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on metastatic breast cancer.

Literature DB >> 11122792

Update on metastatic breast cancer.

E A Perez¹.

Abstract

Entities: Disease

Mesh：

Year: 1999 PMID： 11122792 DOI： 10.1007/s11912-999-0004-8

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

× No keyword cloud information.

18 in total

Review 1. 5-HT3 antiemetic therapy for patients with breast cancer.

Authors: E A Perez
Journal: Breast Cancer Res Treat Date: 1999-09 Impact factor: 4.872

Review 2. Antiangiogenesis for cancer therapy.

Authors: A L Harris
Journal: Lancet Date: 1997-05 Impact factor: 79.321

3. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.

Authors: E A Perez; D W Hillman; P J Stella; J E Krook; L C Hartmann; T R Fitch; A K Hatfield; J A Mailliard; S Nair; C G Kardinal; J N Ingle
Journal: Cancer Date: 2000-01-01 Impact factor: 6.860

4. Cancer statistics, 1999.

Authors: S H Landis; T Murray; S Bolden; P A Wingo
Journal: CA Cancer J Clin Date: 1999 Jan-Feb Impact factor: 508.702

5. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.

Authors: C L Shapiro; T Ervin; L Welles; N Azarnia; J Keating; D F Hayes
Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544

6. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

Authors: V Valero; A U Buzdar; R L Theriault; N Azarnia; G A Fonseca; J Willey; M Ewer; R S Walters; B Mackay; D Podoloff; D Booser; L W Lee; G N Hortobagyi
Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544

Review 7. Taxanes in the treatment of breast cancer: a prodigy comes of age.

Authors: K D Miller; G W Sledge
Journal: Cancer Invest Date: 1999 Impact factor: 2.176

8. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors: R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544

Review 9. The dolastatins, a family of promising antineoplastic agents.

Authors: J Poncet
Journal: Curr Pharm Des Date: 1999-03 Impact factor: 3.116

10. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Authors: G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma
Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544

1 in total

Review 1. Osteopontin: an effector and an effect of tumor metastasis.

Authors: L A Shevde; S Das; D W Clark; R S Samant
Journal: Curr Mol Med Date: 2010-02 Impact factor: 2.222

1 in total